- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Company focuses on pediatrics
Ascent Pediatrics Inc., Wilmington, DE, a new pharmaceutical firm devoted exclusively to products for children, launched its first three products in November of 1997.
Ascent Pediatrics Inc., Wilmington, DE, a new pharmaceutical firm devoted exclusively to products for children, launched its first three products in November of 1997.
The products are Feverall,® an acetaminophen suppository brand for fever reduction and pain relief; Just for Kids⢠Vitamin Drops, a liquid multivitamin; and Pediamist,® a nasal saline mist for relief of dry nasal passages. To specifically meet the needs of children, the products were developed to taste good, require reduced dosing frequency, have minimal side-effects and employ improved delivery systems.
A sales force of 65 pediatric sales specialists will contact pediatricians nationwide about the new products and the need for increased compliance among children. The pediatric market of children under the age of 12 in the United States is estimated at approximately 47 million.
"Children are not miniature adults and their needs are not the same as adults," said Emmett Clemente, Ph.D., Ascent Pediatric's founder and chairman. "Our strategy at Ascent is to meet the challenge of developing products with the goal of increasing compliance among children. After all, what good is a medicine if a child doesn't take it?" PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
